GRI Bio, Inc.
GRINext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for GRI. That does not mean none is planned.
Get an email about GRI's next catalysts
Track GRI Bio (GRI) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Tazarotene (GRI-0621) | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
Frequently asked questions
What is in GRI Bio, Inc.'s drug pipeline?β
CatalystAlert tracks 1 drug candidate in GRI Bio, Inc.'s (GRI) pipeline across Phase 2. Its lead program is Tazarotene (GRI-0621) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is GRI Bio, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for GRI Bio, Inc. (GRI) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track GRI biotech catalysts?β
Add GRI to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow GRI Bio, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
